NCT05605964: An ongoing trial by Sumitomo Pharma Switzerland GmbH
This trial is ongoing. It must report results 5 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05605964 |
|---|---|
| Title | Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 25, 2023 |
| Completion date | Jan. 2, 2025 |
| Required reporting date | Jan. 2, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | July 14, 2025 |
| Days late | None |